Tris Pharma launches online resource for clinicians prescribing ADHD treatment

Tris Pharma Inc. recently announced the launch of a new website for health care professionals prescribing Dyanavel XR, extended-release oral suspension, CII, an extended-release liquid amphetamine, for attention-deficit/hyperactivity disorder in children aged 6 years and older.

“We are excited to offer this new online resource to help health care providers make informed decisions about prescribing Dyanavel XR as a new treatment option for their pediatric patients with ADHD,” Ketan Mehta, MS, president and CEO of Tris Pharma Inc., said in a press release.

The online resource, accessed at http://www.dyanavelxrpro.com, will allow health care professionals to quickly and easily view prescribing information for Dyanavel XR, including clinical efficacy, safety data and other product information.

The website features a pharmacy locater to identify pharmacies that carry Dyanavel XR, a copay assistance program for eligible patients and a toll-free number to arrange home delivery service.

The resource will also include tools to help clinicians familiarize themselves with the ADHD treatment, including a customized dosing tab with an educational visual on dosing and administration.

“Tris Pharma is committed to leveraging innovative technology to bring age-appropriate formulations to address unmet medical needs for pediatric patients,” Mehta said in the release. “By providing physicians with this convenient online resource to information on the safety and clinical efficacy of Dyanavel XR, we hope to help them select the appropriate treatment option for their patients.”